

Dear Colleagues and Guests

The field of preclinical and clinical lymphoma research has seen a dramatic acceleration of progress during the last years, ranging from a molecular characterization of the disease to the development of novel mouse models, as well as preclinical drug development, ultimately culminating in massive advances in our current treatment algorithms, now involving CAR-T cells, various novel (bispecific) antibodies and new small molecule compounds.

In parallel to these scientific developments, within the state of Northrhine-Westphalia, the large comprehensive cancer centers CIO-ABCD (Aachen, Bonn, Cologne, Düsseldorf) and WTZ-EM (Essen, Münster) have strategically strengthened their collaboration, particularly through the establishment of the National Cancer Center West NCT-West (Essen, Cologne), and have further consolidated and expanded their clinical and translational lymphoma programs.

Given these developments, we are excited to launch the bi-annual West German Lymphoma Symposium, to facilitate the scientific exchange within the region, excite young researchers for lymphoma research, and, most importantly, to further expand our international visibility and outreach.

The organizing team of the West German Lymphoma Symposium is happy to invite you to be part of our inaugural meeting. The meeting will take place on 24th and 25th of May 2024 in Essen, Germany at the heart of the Ruhrgebiet.

We would be absolutely thrilled if you could join us for this event. You are cordially invited to submit an Abstract. There will be short talks selected from the best abstracts, as well as poster awards.

With all our best wishes and warm regards
Conference chair

Christian Reinhardt, Prof. Dr

Bastian v. Tresckow, Prof. Dr

Ralf Küppers, Prof. Dr

University Hospital Essen, West German Cancer Center

Peter Borchmann, Prof. Dr

University Hospital Cologne, Clinic for Internal Medicine
Oncology/ Haematology

Sascha Dietrich, Prof. Dr

University Hospital Düsseldorf
Clinic for Haematology, Oncology and Clinical Immunology

Under the auspices of

Scientific lead and response for the programme



Universitätsmedizin Essen

Department of Haematology and Stem Cell Transplantation
West German Cancer Center
University Hospital Essen (AöR)
Hufelandstraße 55, 45147 Essen (Germany)

Meeting Office / Organizer and Contact

CSi Hamburg GmbH
Goernestraße 30, 20249 Hamburg (Germany)
+49 40 30770300
meetings@csihamburg.de



Venue

Conference Center Essen
Huysenallee 55
45128 Essen (Germany)
Nordrhein-Westfalen (NRW)



Hybrid Event

In co-operation with



Start your registration
<https://www.lymphoma-symposium.de>



CLINIC MEETS BIOLOGY

WEST GERMAN LYMPHOMA SYMPOSIUM

www.lymphoma-symposium.de

24th and 25th May 2024

Conference Center Essen (Germany)

PRELIMINARY PROGRAMME

DAY 1	FRIDAY, 24 th MAY 2024	DAY 2	SATURDAY, 25 th MAY 2024	12:45-1:45	Break
from 09:30	Registration			<u>1:45-3:30</u>	Session 5 Mechanisms of resistance and definition of high-risk DLBCL Ralf Küppers, University Hospital Essen (GER)
10:45	Welcome Scientific committee			Chair	
<u>11:00-1:00</u>	Session 1 The germinal center reaction as a catalyst for lymphoma development Christian Reinhardt, University Hospital Essen (GER)	<u>8:00-10:00</u>	Session 3 Genetic rewiring encodes actionable vulnerabilities in lymphoma Sascha Dietrich, University Hospital Düsseldorf (GER)	1:45	Short talk III - „Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas“ S. Scheich, University Hospital Frankfurt, Frankfurt (GER)
Chair		8:00	Genetic bases of immune evasion in lymphoma Margaret Shipp, Dana Farber/Harvard Cancer Center Boston (USA)	1:55	Mechanisms of resistance and definition of high-risk DLBCL Andrew Davies, Southampton General Hospital (UK)
11:00	Role of Super-enhancer Hypermutation in the Pathogenesis of Diffuse Large B cell Lymphoma Riccardo Dalla-Favera, Columbia University New York (USA)	8:25	Curing aggressive lymphomas with aggressive combinations of targeted agents Louis Staudt, National Cancer Institute Bethesda (USA)	2:20	Overcoming therapy resistance through single-cell functional precision medicine approaches Philipp Staber, Medical University of Vienna (AUT)
11:25	Genetics-driven epigenetic disruption of the germinal center program in B cell lymphomas Laura Pasqualucci, Columbia University New York (USA)	8:50	Actionable Alterations in LBCL Björn Chapuy, Charité University Medicine Berlin (GER)	2:45	Autochthonous mouse models of DLBCL enable in vivo genetic screening and serve as a platform for preclinical validation of actionable vulnerabilities Christian Reinhardt, University Hospital Essen (GER)
11:50	Aspects of Hodgkin lymphoma biology Ralf Küppers, University Hospital Essen (GER)	9:15	Elucidation of Lymphoma Proteogenotypes Thomas Oellerich, University Hospital Frankfurt (GER)	3:10	Discussion
12:15	Modelling Sporadic Oncogenic Events in Lymphoma genesis Dinis Calado, The Francis Crick Institute London (UK)	9:40	Short talk II - „Autonomous B-cell receptor signaling in activated B-cell DLBCL: A lymphomagenic driver with functional equivalence to an activating CARD11 variant Hendrik Veelken, Leiden University Medical Center (NL)	3:30	Closing remarks Farewell and Goodbye
12:40	Short talk I - „Unveiling Follicular Lymphoma’s Common Progenitor Cells“ Oscar Atkins, The Francis Crick Institute (UK)	9:50	Discussion		
12:50	Discussion	10:00-10:30	Break		
1:00-2:00	Break	<u>10:30-12:45</u>	Session 4 The next frontier: harnessing the immune system for lymphoma therapy Bastian von Tresckow, University Hospital Essen (GER)		Status May 2024. Subject to change
<u>2:00-4:00</u>	Session 2 Epigenetic rewiring as a driver and target of lymphomagenesis Peter Borchmann, University Hospital Cologne (GER)	Chair			
Chair		10:30	Chemotherapy free approaches in first line LBCL - a dream or a reality? Jason Westin, University of Texas MD Anderson Cancer Center Houston (USA)		
2:00	Mechanisms and therapeutic targeting of the malignant immune system Ari M. Melnick, Weill Cornell Medicine New York (USA)	10:55	Enhancing immunotherapies for germinal center-derived B cell lymphomas by EZH2 inhibition Wendy Béguelin, Weill Cornell Medicine New York, (USA)		
2:25	Development of small molecules for epigenetic targets Stefan Knapp, Goethe-University Frankfurt (GER)	11:20	Multi-omic profiling of CAR T cell treated aggressive B-cell lymphoma reveals a CSF1R+ myeloid-monocytic cell compartment mediating CAR T cell resistance Roland Ullrich, University Hospital Cologne (GER)		
2:50	Harnessing state switches in aggressive B-cell lymphoma Clemens Schmitt, Charité - University Hospital Berlin (GER)	11:45	Bispecific T Cell Engagers in Follicular Lymphoma: Promises and Path Ahead Elisabeth Budde, City of Hope National Medical Center Duarte (USA)		
3:15	DNA-methylation based classification of lymphomas: A tool to come? Reiner Siebert, Ulm University Hospital (GER)	12:10	Multimodal and spatially resolved profiling identifies distinct patterns of T cell infiltration in nodal B cell lymphoma entities Sascha Dietrich, University Hospital Düsseldorf (GER)		
3:40	Toward the noninvasive characterization of lymphomas & their microenvironments Ash A. Alizadeh, Stanford University / Stanford Comprehensive Cancer Center (USA)	12:35	Discussion		
REMOTE					
4:00-6:00	Poster presentation and Get-together				

SPONSORS - Thank you for the support



In accordance with the recommendations of the German Medical Association, the Association of Scientific Medical Societies and the Voluntary Self-Regulation of the Pharmaceutical Industry (FSA Code of Conduct for Healthcare Professionals, Section 20 (5)), the contributions (net amounts, before deduction of costs) of the industry partnerships are disclosed. The above-mentioned companies are participating in the West German Lymphoma Symposium in return for services. Net amounts, before deduction of costs. AbbVie Deutschland GmbH & Co. KG, 50,000 € - BeiGene, 5,000 € - Bristol-Myers Squibb GmbH & Co. KGaA, 20,000 € - Incyte Inc., 10,000 € - Janssen-Cilag GmbH, 5,000 € - Lilly Deutschland GmbH, 50,000 € - MSD Sharp & Dohme GmbH, 5,000 € - Roche Pharma AG, 50,000 € - sobi GmbH, 5,000 € - Takeda Pharma Vertrieb GmbH & Co. KG, 5,000 € - Status: 05/2024